Ladenburg initiated coverage of Fractyl Health (GUTS) with a Buy rating and $3.60 price target Fractyl is “advancing a differentiated approach to obesity” through its Revita duodenal mucosal resurfacing system, which has a “clearly defined” clinical development pathway, the analyst tells investors. The REMAIN-1 study will deliver initial readouts in late 2025, followed by pivotal six-month data from the 315-patient trial in the second half of next year, giving Fractyl multiple catalysts into 2026, the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health price target lowered to $6 from $12 at Canaccord
- Fractyl Health’s Earnings Call: Strategic Gains Amid Financial Challenges
- Fractyl Health Reports Q2 2025 Financial Results and Progress
- Fractyl Health, Inc.: Promising Developments and Strategic Focus Justify Buy Rating
- GUTS Earnings Report this Week: Is It a Buy, Ahead of Earnings?